Your browser doesn't support javascript.
loading
Recent advances in anti-multidrug resistance for nano-drug delivery system.
Wang, Changduo; Li, Fashun; Zhang, Tianao; Yu, Min; Sun, Yong.
Afiliação
  • Wang C; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, China.
  • Li F; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, China.
  • Zhang T; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, China.
  • Yu M; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, China.
  • Sun Y; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, China.
Drug Deliv ; 29(1): 1684-1697, 2022 Dec.
Article em En | MEDLINE | ID: mdl-35616278
Chemotherapy for tumors occasionally results in drug resistance, which is the major reason for the treatment failure. Higher drug doses could improve the therapeutic effect, but higher toxicity limits the further treatment. For overcoming drug resistance, functional nano-drug delivery system (NDDS) has been explored to sensitize the anticancer drugs and decrease its side effects, which are applied in combating multidrug resistance (MDR) via a variety of mechanisms including bypassing drug efflux, controlling drug release, and disturbing metabolism. This review starts with a brief report on the major MDR causes. Furthermore, we searched the papers from NDDS and introduced the recent advances in sensitizing the chemotherapeutic drugs against MDR tumors. Finally, we concluded that the NDDS was based on several mechanisms, and we looked forward to the future in this field.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas / Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Drug Deliv Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas / Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Drug Deliv Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China